Grace Therapeutics Earnings Estimate
| GRCE Stock | 3.60 0.12 3.45% |
Grace Therapeutics Earnings Estimation Breakdown
The calculation of Grace Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Grace Therapeutics is estimated to be -0.393 with the future projection ranging from a low of -0.393 to a high of -0.393. Please be aware that this consensus of annual earnings estimates for Grace Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.39 Lowest | Expected EPS | -0.39 Highest |
Grace Therapeutics Earnings Projection Consensus
Suppose the current estimates of Grace Therapeutics' value are higher than the current market price of the Grace Therapeutics stock. In this case, investors may conclude that Grace Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Grace Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 2 | 64.54% | -0.0841 | -0.393 | -0.52 |
Grace Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Grace Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Grace Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Grace Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Grace Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Grace Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Grace Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Grace Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Grace Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-12 | 2025-09-30 | -0.344 | -0.0841 | 0.2599 | 75 | ||
2025-08-12 | 2025-06-30 | -0.308 | -0.2895 | 0.0185 | 6 | ||
2025-06-23 | 2025-03-31 | -0.3983 | 0.1374 | 0.5357 | 134 | ||
2025-02-17 | 2024-12-31 | -0.4583 | -0.5118 | -0.0535 | 11 | ||
2024-11-13 | 2024-09-30 | -0.5027 | -0.4183 | 0.0844 | 16 | ||
2024-08-09 | 2024-06-30 | -0.362 | -0.3296 | 0.0324 | 8 | ||
2024-06-21 | 2024-03-31 | -0.47 | -0.3566 | 0.1134 | 24 |
About Grace Therapeutics Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Grace Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Grace Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Grace Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -198.6 M | -188.7 M | |
| Earnings Yield | (0.31) | (0.33) | |
| Price Earnings Ratio | (3.31) | (3.15) | |
| Price Earnings To Growth Ratio | 0.05 | 0.05 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Grace Therapeutics is a strong investment it is important to analyze Grace Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Grace Therapeutics' future performance. For an informed investment choice regarding Grace Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Grace Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. For information on how to trade Grace Stock refer to our How to Trade Grace Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Will Pharmaceuticals sector continue expanding? Could Grace diversify its offerings? Factors like these will boost the valuation of Grace Therapeutics. Market participants price Grace higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Grace Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Grace Therapeutics requires distinguishing between market price and book value, where the latter reflects Grace's accounting equity. The concept of intrinsic value - what Grace Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Grace Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Grace Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Grace Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Grace Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.